Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $15.9652W HIGH $27.50
Volume
1.74 M
Value Traded
39.63 M
Short % Float
6.82%
Days to Cover
9.0
+1.16%Week
-5.25%1 Month
+30.58%3 Month
+11.24%6 Month
-88.53%5 Year
-23.26%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.77 B
EPS (TTM)
-1.68
P/E Ratio
-
Ent. Value
2.39 B
Total Shares
113.78 M
Float Shares
104.83 M
Insiders
7.07%
Institutions
35.83%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ZLAB Catalyst Timeline
Dated clinical, regulatory and corporate events for Zai Lab Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zai Lab Limited
618Total events
32Upcoming
268Tier-1 (high impact)
2017 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Investor conference call/webcast to discuss ESMO 2026 data and zoci trial plans
▼Equity OfferingCorporate
Zai Lab announces $250 million PIPE private placement of 11,340,000 ADSs at $22.04 per ADS
▲Topline ReadoutZL-1310Clinical Data
First Phase 1b data for zoci + atezolizumab ± carboplatin in 1L ES-SCLC (ORR 81.8% doublet)
extensive-stage small cell lung cancer (ES-SCLC), first-linesource ↗
▼Equity OfferingCorporate
Zai Lab enters securities purchase agreement for $250M PIPE private placement of 11,340,000 ADSs at $22.04 per ADS
▲Topline ReadoutefgartigimodApprovedClinical Data
Positive topline results from Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis
autoimmune myositissource ↗
▲Primary Endpoint MetefgartigimodApprovedClinical Data
ALKIVIA Phase 3 met primary endpoint of mean TIS at Week 52 in combined IMNM and DM population
autoimmune myositissource ↗
▼Primary Endpoint MissedefgartigimodApprovedClinical Data
ALKIVIA Phase 3 DM subtype did not reach statistical significance (p=0.1093)
dermatomyositis (DM)source ↗
▲Orphan Drug DesignationZL-1310Designation
FDA granted Orphan Drug Designation to zoci for NECs
neuroendocrine carcinomas (NECs)source ↗
▲EU Orphan DesignationZL-1310Ex-US Regulatory
EMA granted ODD for zoci in pulmonary NECs
pulmonary NECssource ↗
▲EU Orphan DesignationZL-1310Ex-US Regulatory
EMA Orphan Drug Designation for Zoci in Pulmonary Neuroendocrine Carcinomas
Pulmonary Neuroendocrine Carcinomassource ↗
▲NMPA NDA ApprovalTIVDAKEx-US Regulatory
NMPA approval of TIVDAK for recurrent or metastatic cervical cancer
recurrent or metastatic cervical cancersource ↗
▲Fast Track DesignationZL-1310Designation
FDA Fast Track Designation for Zoci in epNECs
Extrapulmonary Neuroendocrine Carcinomas (epNECs)source ↗
◆PDUFA DateefgartigimodApprovedRegulatory Filing
PDUFA target action date for sn-gMG sBLA
seronegative generalized myasthenia gravissource ↗
◆Poster PresentationZL-1222Presentation
ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity
cancer immunotherapysource ↗
◆Poster PresentationZL-1310Presentation
Preliminary results from phase 1b/2 study of ZL-1310 in neuroendocrine carcinomas and other solid tumors
neuroendocrine carcinomas and other selected solid tumorssource ↗
▲Oral PresentationZL-1310Presentation
Intracranial activity of ZL-1310 in ES-SCLC with brain metastases presented at AACR 2026
extensive stage small cell lung cancer (ES-SCLC) with brain metastasessource ↗
●Oral PresentationZL-6201Presentation
Preclinical data for ZL-6201 (LRRC15 ADC) presented at AACR 2026
sarcoma and epithelial tumorssource ↗
●Oral PresentationZL-1222Presentation
Preclinical data for ZL-1222 (PD-1/IL-12 immunocytokine) presented at AACR 2026
cancer immunotherapysource ↗
◆Poster PresentationZL-6201Presentation
Discovery of ZL-6201, a novel LRRC15-targeting ADC for sarcomas and epithelial solid tumors
sarcomas and epithelial solid tumorssource ↗
▲Poster PresentationZL-1503Presentation
Poster presentation of preclinical data for ZL-1503 at IMMUNOLOGY2026
atopic dermatitis, asthma, allergic conjunctivitis, rhinitissource ↗
▲Partnership / LicenseCorporate
Boehringer Ingelheim and Zai Lab announce clinical collaboration for DLL3-targeting combination therapy
◆Topline ReadoutZL-1503Clinical Data
Clinical data expected from Phase 1/1b study of ZL-1503
moderate-to-severe atopic dermatitissource ↗
▲Partnership / LicenseCorporate
Global clinical trial collaboration and supply agreement with Amgen to evaluate zocilurtatug pelitecan in combination with IMDELLTRA
▲Oral PresentationZL-1310Presentation
Presented clinical data at AACR 2026 showing intracranial responses in SCLC and activity in epNECs
ES-SCLC with brain metastases; epNECssource ↗
▲Partnership / LicenseZL-1310Corporate
Announced global clinical trial collaboration with Amgen (IMDELLTRA) and Boehringer Ingelheim (obrixtamig)
ES-SCLC; SCLC and other NECssource ↗
◆Topline ReadoutZL-1310Clinical Data
Data readout from Phase 1 combination study (with atezolizumab and/or chemotherapy)
First-line ES-SCLCsource ↗
▲Topline ReadoutpovetaciceptClinical Data
Positive Week 36 interim analysis: 52.0% UPCR reduction vs placebo (p<0.0001)
IgA nephropathysource ↗
▲Enrollment CompletepovetaciceptTrial
Completed enrollment in Phase 2 portion of OLYMPUS study
Primary membranous nephropathysource ↗
▲Topline ReadoutElegrobartClinical Data
Positive topline data in both REVEAL-1 (active TED) and REVEAL-2 (chronic TED) – primary endpoints met
Active TED; Chronic TEDsource ↗
▲Partnership / LicenseZL-1311Corporate
Obtained exclusive worldwide rights to develop and commercialize ZL-1311
gastric and gastroesophageal junction cancerssource ↗
▲Partnership / LicenseAUGTYROApprovedCorporate
Strategic collaboration with SciClone for AUGTYRO commercialization in mainland China
ROS1-positive NSCLC and NTRK-positive solid tumorssource ↗
▲Primary Endpoint MetVYVGARTApprovedClinical Data
ADAPT OCULUS met primary endpoint with p-value=0.012
ocular myasthenia gravis (oMG)source ↗
▲Topline ReadoutVYVGARTApprovedClinical Data
Topline results from ADAPT OCULUS announced
ocular myasthenia gravis (oMG)source ↗
▲Primary Endpoint MetVYVGARTApprovedClinical Data
Phase 3 ADAPT OCULUS met primary endpoint in oMG
ocular myasthenia gravissource ↗
●Oral PresentationPresentation
Zai Lab presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchCOBENFYApprovedPost-Market
COBENFY commercial launch in China expected in 1H 2026
▲First Patient DosedZL-1310Trial
First patient dosed in global Phase 2 portion of Phase 1b/2 study in extrapulmonary NECs
extrapulmonary NECssource ↗
▲FDA Filing AcceptedefgartigimodApprovedRegulatory Filing
FDA accepted for Priority Review sBLA for sn-gMG
seronegative generalized myasthenia gravissource ↗
◆Topline ReadoutZL-1310Clinical Data
Initial data readout from Phase 1b portion in extrapulmonary NECs
extrapulmonary NECssource ↗
▲FDA ApprovalAUGTYROApprovedFDA Decision
NMPA approval for NTRK-positive solid tumors in mainland China
NTRK-positive solid tumorssource ↗
◆Topline ReadoutefgartigimodApprovedClinical Data
Topline results from Phase 3 ADAPT-OCULUS study expected in H1 2026
ocular myasthenia gravissource ↗
Past FDA Catalysts and PDUFA Decisions
How ZLAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-17 | efgartigimod (FcRn) | Phase 2/3 topline data readout | Phase 2/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Top 5%
Small Cap(rank 34 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ZEJULA | |||
| Vyvgart/Vyvgart Hytrulo | |||
| NUZYRA | |||
| OPTUNE | |||
| QINLOCK | |||
| XACDURO | |||
| AUGTYRO | |||
| KarXT |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZL-1310 Small moleculeNCT07707895 | Small Cell Lung Cancer | Phase 3 | NOT YET_RECRUITING | 540 | Apr 26, 2030 | ||||||
| ZL-1310 Small moleculeNCT07796100 | Extensive-Stage Small Cell Lung Cancer | Phase 3 | NOT YET_RECRUITING | 530 | Jun 30, 2031 | ||||||
| ZL-1310 Small moleculeNCT06179069 | SCLC | Phase 1 | RECRUITING | 339 | Jul 31, 2027 | ||||||
| ZL-1310 Small moleculeNCT06885281 | Solid Tumors | Phase 1 | RECRUITING | 166 | Apr 1, 2028 | ||||||
| ZL-1503 Small moleculeNCT07235384 | Atopic Dermatitis (AD) | Phase 1 | RECRUITING | 84 | Dec 28, 2027 | ||||||
| ZL-1109 Small moleculeNCT07211776 | Thyroid Eye Disease (TED) | Phase 3 | ACTIVE NOT_RECRUITING | 108 | Jan 29, 2028 | ||||||
| ZL-6201 Small moleculeNCT07374848 | Solid Tumors | Phase 1 | RECRUITING | 180 | Sep 1, 2029 | ||||||
| ZL-1211 Small moleculeCompletedNCT05065710 | Advanced Solid Tumor | Phase 1 | COMPLETED | 34 | Apr 9, 2024 | ||||||
| ZL-1201 Small moleculeCompletedNCT04257617 | Advanced Cancer | Phase 1 | COMPLETED | 37 | Jan 19, 2023 | ||||||
| ZL-2306 Niraparib） Small moleculeCompletedNCT04392102 | Ovarian Cancer | Phase 2 | COMPLETED | 15 | Aug 11, 2022 | ||||||
| Ripretinib Small moleculeMarketedNCT04633122 | Gastrointestinal Stromal Tumor(GIST) | Phase 2 | COMPLETED | 108 | Jul 20, 2022 | ||||||
| DCC-2618 Small moleculeMarketedNCT04282980 | Gastrointestinal Stromal Tumors | Phase 2 | COMPLETED | 39 | Aug 23, 2022 | ||||||
| Tisotumab Vedotin ADCMarketedNCT05866354 | Solid Malignancies | Phase 1 | COMPLETED | 19 | Nov 2, 2023 | ||||||
| Omadacycline Small moleculeMarketedNCT06462326 | Undisclosed | Phase 1 | COMPLETED | 24 | Sep 29, 2024 | ||||||
| ZL-2306 Small moleculeMarketedNCT03551171 | Ovarian Cancer | Phase 1 | COMPLETED | 42 | Jul 10, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every ZLAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| zocilurtatug pelitecan Fast TrackOrphan | extensive-stage small cell lung cancer | Phase 1b | 2026-10-23 | high response rates and encouraging durabilityRead More | Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Chen YajingOfficer (Chief Financial Officer) | Option | 920 36,555 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZLAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.1 % (-8.3 %) | 124.91 M | 6.57 M |
ZLAB Institutional Ownership Trends
ZLAB Short Interest
Shares sold short, counted twice a month.
6.82%
Short % of Float
of tradable shares sold short
7.1M
Shares Sold Short
-12.3% vs prior count
9.0 High
Days to Cover
trading days of normal volume to buy every short share back
791.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZLAB ranks across every disease it competes in
Competitive Position is a premium feature
See how ZLAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZLAB News
ZLAB▲ +9%on this news
Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Zai Lab's zocilurtatug pelitecan (Zoci) in combination with atezolizumab showed an 81.8% objective response rate in extensive-stage small cell lung cancer patients. The treatment demonstrated a favorable safety profile with only 9.1% of patients experiencing severe adverse events. A global Phase 3 study is expected to start by the end of 2026.
Read more →ZLAB▲ +9%on this newsshared move
Zai Lab Announces $250 Million Private Placement
Zai Lab Limited announced a $250 million private placement of 11,340,000 ADSs at $22.04 each. The financing, led by TCGX, aims to support the global development of zocilurtatug pelitecan, a DLL3-targeting ADC. The transaction is expected to close on or about October 27, 2026, subject to customary conditions.
Read more →ZLABZai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Zai Lab Limited will announce its third quarter 2026 financial results on November 5, 2026. The announcement will precede a conference call and webcast at 8:00 a.m. ET. Participants must register in advance to join the call and access the live webcast.
Read more →ZLABZai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
Zai Lab announced that data from the first clinical trial of ZL-1503, a bispecific antibody targeting IL-13 and IL-31, will be presented at the ACAAI 2026 Annual Scientific Meeting. This innovative treatment aims to alleviate symptoms of atopic diseases, showing promise in preclinical studies for rapid itch relief. The trial's findings will include pharmacokinetic and safety data.
Read more →ZLABZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Zai Lab Limited announced that it will present the first global data from a clinical trial evaluating zocilurtatug pelitecan (Zoci) for extensive-stage small cell lung cancer. This presentation will take place at the ESMO Congress 2026 in Madrid, highlighting the potential of Zoci as a first-line treatment option.
Read more →ZLABZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Zai Lab and argenx have reported positive topline results from the Phase 3 ALKIVIA trial of efgartigimod in adults with autoimmune myositis. The study successfully met its primary endpoint, demonstrating statistical significance in the combined population of immune-mediated necrotizing myopathy and dermatomyositis. This outcome highlights the potential of efgartigimod as a treatment option.
Read more →ZLAB▲ +13.7%on this news· ran to +42% by day 3
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab Limited has reported its financial results for the second quarter of 2026, showcasing significant corporate updates and product highlights. CEO Dr. Samantha Du emphasized the company's evolution from a local player in China to a global biopharmaceutical entity. The announcement marks a pivotal moment in Zai Lab's growth trajectory.
Read more →ZLABU.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Zai Lab Limited has received Orphan Drug Designation from the U.S. FDA for zocilurtatug pelitecan (Zoci), a DLL3-targeting ADC aimed at treating neuroendocrine carcinomas (NECs). This designation highlights the drug's potential as a first-in-class therapy for these aggressive malignancies, which currently lack targeted treatment options.
Read more →ZLABZai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Zai Lab Limited will report its second quarter 2026 financial results on August 6, 2026. The announcement will occur before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET. This event will provide insights into the company's recent corporate developments.
Read more →ZLABZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Zai Lab has been granted orphan drug designation by the European Medicines Agency for Zocilurtatug Pelitecan, aimed at treating pulmonary neuroendocrine carcinomas. This designation is expected to facilitate the drug's development and potential approval in the European market. The orphan status highlights the drug's significance for rare diseases.
Read more →ZLABZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab has received approval from China's NMPA for TIVDAK (tisotumab vedotin) to treat adult patients with recurrent or metastatic cervical cancer. This approval follows the successful results of the Phase 3 innovaTV 301 clinical trial. TIVDAK is indicated for patients who have experienced disease progression after chemotherapy.
Read more →ZLABargenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Read more →ZLABVertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy
Read more →ZLABZai Lab Announces Changes to Senior Leadership Team - May 21, 2026
Zai Lab Limited announced changes to its senior leadership team, including the departure of President and COO Josh Smiley. The company aims to enhance operational performance and efficiency. Zai Lab is also preparing for significant clinical data readouts in 2026 and the launch of COBENFY™ in China, alongside multiple regional regulatory approvals.
Read more →ZLABZai Lab Announces Changes to Senior Leadership Team
Zai Lab has announced changes to its senior leadership team. The article does not provide specific details about the changes or their implications for the company. This announcement may indicate a strategic shift within the organization. Further information is needed to assess the impact of these leadership changes.
Read more →ZLAB▲ +5.3%on this news
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Zai Lab has been granted Fast Track designation by the U.S. FDA for its investigational drug, Zocilurtatug Pelitecan (Zoci). This drug is a DLL3-targeting antibody-drug conjugate aimed at treating extrapulmonary neuroendocrine carcinomas (epNECs). The designation is expected to facilitate faster development and review of the drug.
Read more →ZLAB▼ -5.9%on this newsshared move
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
argenx SE announced that the U.S. FDA has approved a label expansion for VYVGART and VYVGART Hytrulo, allowing their use in all adult patients with generalized myasthenia gravis (gMG), regardless of serotype. This approval is based on positive results from the Phase 3 ADAPT SERON study, which demonstrated significant symptom improvements in patients. The expanded indication aims to meet the needs of gMG patients who previously lacked effective treatment options.
Read more →ZLAB▼ -5.9%on this newsshared move
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab Limited reported its financial results for Q1 2026, highlighting a decrease in total revenue to $99.6 million, down 6% year-over-year. Despite challenges, the company made significant advancements in its oncology pipeline, particularly with zoci, and is preparing for the launch of KarXT in China. The company also noted increased R&D expenses and a net loss of $51 million, reflecting ongoing investments in its clinical programs.
Read more →ZLABViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Read more →ZLAB▼ -6.4%on this news
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited will report its first quarter 2026 financial results on May 7, 2026. The announcement will occur before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET. Participants must register in advance to join the call, which will also be available for replay afterward.
Read more →About Zai Lab Limited
Headquarters899 HALEI ROAD, SHANGHAI
BIOPHARMAWATCH ELITE PLUS
Trade the next ZLAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime